Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Rating Lowered by BidaskClub

Share on StockTwits

BidaskClub cut shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a buy rating to a hold rating in a report published on Saturday, BidAskClub reports.

A number of other analysts have also issued reports on ENTA. Zacks Investment Research raised Enanta Pharmaceuticals from a hold rating to a buy rating and set a $99.00 price target on the stock in a research note on Friday, May 10th. Wolfe Research initiated coverage on Enanta Pharmaceuticals in a research note on Friday, May 24th. They issued an outperform rating and a $117.00 price objective on the stock. Finally, Berenberg Bank raised Enanta Pharmaceuticals from a hold rating to a buy rating and lifted their price objective for the company from $80.00 to $120.00 in a research note on Tuesday, April 23rd. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Enanta Pharmaceuticals presently has a consensus rating of Buy and an average price target of $111.20.

Shares of NASDAQ:ENTA opened at $82.09 on Friday. The stock has a 50-day simple moving average of $90.18. Enanta Pharmaceuticals has a 12-month low of $64.08 and a 12-month high of $127.77. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of 23.59 and a beta of 1.18.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.29. Enanta Pharmaceuticals had a return on equity of 19.25% and a net margin of 33.28%. The firm had revenue of $39.60 million for the quarter, compared to analyst estimates of $40.92 million. During the same period last year, the company earned $0.61 EPS. The firm’s quarterly revenue was down 10.0% on a year-over-year basis. Research analysts predict that Enanta Pharmaceuticals will post 1.9 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ENTA. Marshall Wace North America L.P. lifted its stake in shares of Enanta Pharmaceuticals by 1,128.7% in the 1st quarter. Marshall Wace North America L.P. now owns 225,694 shares of the biotechnology company’s stock valued at $21,558,000 after purchasing an additional 207,326 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of Enanta Pharmaceuticals by 17.0% in the 1st quarter. Janus Henderson Group PLC now owns 874,397 shares of the biotechnology company’s stock valued at $83,522,000 after purchasing an additional 126,804 shares in the last quarter. Norges Bank acquired a new position in shares of Enanta Pharmaceuticals in the 4th quarter valued at about $7,106,000. Citigroup Inc. lifted its stake in shares of Enanta Pharmaceuticals by 875.0% in the 4th quarter. Citigroup Inc. now owns 69,495 shares of the biotechnology company’s stock valued at $4,922,000 after purchasing an additional 62,367 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. acquired a new position in shares of Enanta Pharmaceuticals in the 4th quarter valued at about $4,391,000. 89.49% of the stock is currently owned by institutional investors and hedge funds.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

Featured Story: Why is the Consumer Price Index (CPI) important?

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.